[{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HY07121","moa":"Unknown","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Phase I","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd."},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd."},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Suzhou Guochen Biotechnology Co., Ltd. | Jeeyor Medical Research | Boji Medical Technology | The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Suzhou Guochen Biotechnology Co., Ltd. | Jeeyor Medical Research | Boji Medical Technology | The First Hospital of Jilin University","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Suzhou Guochen Biotechnology Co., Ltd. | Jeeyor Medical Research | Boji Medical Technology | The First Hospital of Jilin University"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HYP-6589","moa":"SOS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HYP-2090PTSA","moa":"Class 1 PI3K\/KRAS G12C","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"HY-2003","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital"}]

Find Clinical Drug Pipeline Developments & Deals by Sichuan Huiyu Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Lead Product(s) : Ferric Carboxymaltose

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Suzhou Guochen Biotechnology Co., Ltd. | Jeeyor Medical Research | Boji Medical Technology | The First Hospital of Jilin University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          March 26, 2025

                          Lead Product(s) : Ferric Carboxymaltose

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Suzhou Guochen Biotechnology Co., Ltd. | Jeeyor Medical Research | Boji Medical Technology | The First Hospital of Jilin University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Lead Product(s) : Paclitaxel

                          Therapeutic Area : Oncology

                          Study Phase : Undisclosed

                          Sponsor : The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          January 09, 2025

                          Lead Product(s) : Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Lead Product(s) : HY-2003

                          Therapeutic Area : Nutrition and Weight Loss

                          Study Phase : Phase I

                          Sponsor : Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 03, 2025

                          Lead Product(s) : HY-2003

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 02, 2024

                          Lead Product(s) : HYP-6589

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Lead Product(s) : Iron Sucrose

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 05, 2024

                          Lead Product(s) : Iron Sucrose

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : HY07121

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Lead Product(s) : Iron Sucrose

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 01, 2024

                          Lead Product(s) : Iron Sucrose

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 06, 2024

                          Lead Product(s) : HYP-2090PTSA

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Lead Product(s) : Ferric Carboxymaltose

                          Therapeutic Area : Hematology

                          Study Phase : Phase I

                          Sponsor : The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          October 12, 2023

                          Lead Product(s) : Ferric Carboxymaltose

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I

                          Sponsor : The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank